• Age: 18 years old ≤ age ≤ 75 years old, both male and female;

• Strictly meet the clinical diagnostic criteria of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) or hepatocellular carcinoma patients diagnosed by histopathological or cytological examinations , and at least one measurable lesion (according to the mRECIST1.1 standard, the long diameter of the measurable lesion on spiral CT scan is ≥10mm or the short diameter of the malignant lymph node is ≥15mm);

• Not previously accepted Patients with hepatocellular carcinoma who have progressed/intolerable and unresectable after systemic therapy or first-line systemic therapy;

• CNLC stage IIb-IIIb;

• Child-Pugh liver function grade A or B (5- 7 points);

• ECOG PS score 0-1 points;

• Expected survival period ≥ 12 weeks;

• If the patient has active hepatitis B virus (HBV) infection: if HBV-DNA ≤ 2000, you can start directly Treatment; if HBV-DNA\>2000, antiviral treatment should be given for one week before starting treatment;

• The subjects volunteered to join the study, had good compliance, and cooperated with follow-up.